Last reviewed · How we verify
HSPPC-96 or Oncophage
HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells.
HSPPC-96 is a personalized cancer vaccine that uses heat shock protein-peptide complexes derived from a patient's own tumor to stimulate immune recognition and destruction of cancer cells. Used for Metastatic melanoma (adjuvant setting), Renal cell carcinoma (adjuvant setting).
At a glance
| Generic name | HSPPC-96 or Oncophage |
|---|---|
| Sponsor | Agenus Inc. |
| Drug class | Autologous therapeutic cancer vaccine |
| Target | Tumor-associated antigens presented via Hsp96 complexes |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HSPPC-96 (Oncophage) is an autologous therapeutic cancer vaccine composed of heat shock protein-96 (Hsp96) complexes bound to tumor-associated peptides isolated from each patient's surgically resected tumor. The vaccine works by presenting these tumor-specific antigens to the immune system, priming dendritic cells and T cells to recognize and attack remaining cancer cells expressing the same antigens. This personalized approach leverages the patient's own tumor biology to generate a targeted anti-tumor immune response.
Approved indications
- Metastatic melanoma (adjuvant setting)
- Renal cell carcinoma (adjuvant setting)
Common side effects
- Injection site reactions (erythema, induration, pruritus)
- Fever
- Fatigue
- Chills
Key clinical trials
- Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma. (EARLY_PHASE1)
- Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (PHASE2)
- Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine (PHASE1)
- GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma (PHASE1, PHASE2)
- HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM (PHASE2)
- Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (PHASE1, PHASE2)
- Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer (PHASE1)
- Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSPPC-96 or Oncophage CI brief — competitive landscape report
- HSPPC-96 or Oncophage updates RSS · CI watch RSS
- Agenus Inc. portfolio CI